Prot #ACT18018: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants with Non-Cystic Fibrosis Bronchiectasis

Project: Research project

Project Details

StatusActive
Effective start/end date10/16/2410/16/27

Funding

  • ICON Clinical Research, LLC (Prot #ACT18018 // Prot #ACT18018)
  • Sanofi US Services Inc. (Prot #ACT18018 // Prot #ACT18018)